Latest news with #JohnHester
Business Insider
4 days ago
- Business
- Business Insider
Bell Potter Reaffirms Their Buy Rating on Cyclopharm Limited (CYC)
In a report released today, John Hester from Bell Potter maintained a Buy rating on Cyclopharm Limited (CYC – Research Report), with a price target of A$2.20. The company's shares closed today at A$1.14. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter According to TipRanks, Hester is a 4-star analyst with an average return of 7.1% and a 50.56% success rate. Hester covers the Healthcare sector, focusing on stocks such as Polynovo , Mesoblast Limited, and Telix Pharmaceuticals. The word on The Street in general, suggests a Hold analyst consensus rating for Cyclopharm Limited. The company has a one-year high of A$2.50 and a one-year low of A$1.03. Currently, Cyclopharm Limited has an average volume of 92.52K.
Business Insider
29-05-2025
- Business
- Business Insider
Bell Potter Sticks to Their Buy Rating for Radiopharm Theranostics Limited (RAD)
In a report released today, John Hester from Bell Potter maintained a Buy rating on Radiopharm Theranostics Limited (RAD – Research Report), with a price target of A$0.05. The company's shares closed today at A$0.03. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter According to TipRanks, Hester is a 4-star analyst with an average return of 7.4% and a 50.57% success rate. Hester covers the Healthcare sector, focusing on stocks such as Polynovo , Mesoblast Limited, and Telix Pharmaceuticals. The analyst consensus on Radiopharm Theranostics Limited is currently a Hold rating.
Business Insider
20-05-2025
- Business
- Business Insider
Positive Report for Paragon Care Limited (PXS) from Bell Potter
Bell Potter analyst John Hester upgraded Paragon Care Limited (PXS – Research Report) to a Buy today and set a price target of A$0.52. The company's shares closed last Friday at €0.23. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter Hester covers the Healthcare sector, focusing on stocks such as Polynovo , Mesoblast Limited, and Telix Pharmaceuticals. According to TipRanks, Hester has an average return of 9.3% and a 53.49% success rate on recommended stocks. Paragon Care Limited has an analyst consensus of Moderate Buy, with a price target consensus of €0.31. The company has a one-year high of €0.32 and a one-year low of €0.20. Currently, Paragon Care Limited has an average volume of 17.
Business Insider
09-05-2025
- Business
- Business Insider
Clarity Pharmaceuticals Ltd. (CU6) Receives a Buy from Bell Potter
In a report released today, John Hester from Bell Potter maintained a Buy rating on Clarity Pharmaceuticals Ltd. (CU6 – Research Report), with a price target of A$5.20. Protect Your Portfolio Against Market Uncertainty Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter. Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox. Hester covers the Healthcare sector, focusing on stocks such as Polynovo , Mesoblast Limited, and Telix Pharmaceuticals. According to TipRanks, Hester has an average return of 7.4% and a 51.76% success rate on recommended stocks. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Clarity Pharmaceuticals Ltd. with a A$6.22 average price target. The company has a one-year high of A$8.98 and a one-year low of A$1.43. Currently, Clarity Pharmaceuticals Ltd. has an average volume of 2.56M.
Business Insider
01-05-2025
- Business
- Business Insider
Mesoblast Limited (MEOBF) Receives a Buy from Bell Potter
Bell Potter analyst John Hester maintained a Buy rating on Mesoblast Limited (MEOBF – Research Report) today and set a price target of A$3.40. Protect Your Portfolio Against Market Uncertainty Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter. Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox. Hester covers the Healthcare sector, focusing on stocks such as Polynovo , Mesoblast Limited, and Telix Pharmaceuticals. According to TipRanks, Hester has an average return of 4.8% and a 50.60% success rate on recommended stocks. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Mesoblast Limited with a $1.86 average price target. Based on Mesoblast Limited's latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $1.58 million and a GAAP net loss of $23.97 million. In comparison, last year the company earned a revenue of $1.69 million and had a GAAP net loss of $16.27 million Based on the recent corporate insider activity of 10 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of MEOBF in relation to earlier this year.
